Cadence Pharmaceuticals Inc. (CADX) Management Discusses Q2 2013 Results (Webcast)

|
 |  About: Mallinckrodt PLC (MNK)
by: SA Transcripts

Cadence (CADX): Q2 EPS of -$0.14 misses by $0.03. Revenue of $24.7M beats by $0.86M. (PR)

The following audio is from an earnings conference call that began on July 31, 2013, at 4:30 PM ET. The audio is live-streaming while the call is active, and can be replayed upon its completion.